A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nanomedicine : nanotechnology, biology, and medicine

• Publication date

  2017-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.nano.2016.10.005PMID 27769887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo

  2016cited by this paper
• Targeted Therapy for Breast Cancer Stem Cells by Liposomal Delivery of siRNA against Fibronectin EDB

  2015cited by this paper
• Effect of PEG Pairing on the Efficiency of Cancer-Targeting Liposomes

  2015cited by this paper
• Co-delivery of doxorubicin and siRNA by a simplified platform with oligodeoxynucleotides as a drug carrier.

  2015cited by this paper
• Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer

  2015cited by this paper
• Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.

  2014cited by this paper
• Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers.

  2014cited by this paper
• Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multi-drug resistant tumors

  2014cited by this paper
• Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.

  2014cited by this paper
• Cancer drug resistance: an evolving paradigm

  2013cited by this paper
• Understanding and targeting cancer stem cells: therapeutic implications and challenges

  2013cited by this paper
• Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy.

  2013cited by this paper
• Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

  2013cited by this paper
• Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer

  2013cited by this paper
• Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.

  2012cited by this paper
• Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides.

  2012cited by this paper
• Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging.

  2012cited by this paper
• Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

  2012cited by this paper
• Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly.

  2012cited by this paper
• Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for Enhanced Anticancer Efficacy

  2011cited by this paper
• Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA.

  2011cited by this paper
• Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.

  2011cited by this paper
• Efficient Liposomal Nanocarrier-mediated Oligodeoxynucleotide Delivery Involving Dual Use of a Cell-Penetrating Peptide as a Packaging and Intracellular Delivery Agent.

  2010cited by this paper
• To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.

  2010cited by this paper
• Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.

  2010cited by this paper
• The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

  2010cited by this paper
• Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.

  2009cited by this paper
• Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

  2009cited by this paper
• Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug

  2009cited by this paper
• Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

  2008cited by this paper
• The biology of cancer stem cells.

  2007cited by this paper
• Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action

  2007cited by this paper
• Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

  2007cited by this paper
• Fibronectin as target for tumor therapy

  2006cited by this paper
• Molecular mechanisms of drug resistance

  2005cited by this paper
• EDB fibronectin and angiogenesis – a novel mechanistic pathway

  2005cited by this paper
• Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis

  2005cited by this paper
• Cancer as a robust system: implications for anticancer therapy

  2004cited by this paper
• Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.

  2003cited by this paper
• Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

  2003cited by this paper
• Cancer robustness: Tumour tactics

  2003cited by this paper
• Controlled targeting of liposomal doxorubicin via the folate receptor in vitro.

  2003cited by this paper
• Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

  2002cited by this paper
• Multicellular resistance: a paradigm for clinical resistance?

  2000cited by this paper
• High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease

  2000cited by this paper
• Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.

  2000cited by this paper
• Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma.

  1997cited by this paper
• Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.

  1990cited by this paper

• Peptide-Based Therapeutic Platforms for Addressing Drug Resistance in Breast Cancer

  2025cites this paper
• Cyclodextrin nanocarriers in Coordination Chemistry: Enhancing encapsulation and targeted delivery of 5-Fluorouracil for cancer treatment

  2024cites this paper
• Recent advanced lipid-based nanomedicines for overcoming cancer resistance

  2024cites this paper
• Increased Expression of the Pathological O-glycosylated Form of Oncofetal Fibronectin in the Multidrug Resistance Phenotype of Cancer Cells.

  2023cites this paper
• Improving Release Profile and Anticancer Activity of 5-Fluorouracil for Breast Cancer Therapy Using a Double Drug Delivery System: Chitosan/Agarose/γ-Alumina Nanocomposite@Double Emulsion

  2023cites this paper
• RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer

  2023cites this paper
• Bittersweet Sugars: How Unusual Glycan Structures May Connect Epithelial-to-Mesenchymal Transition and Multidrug Resistance in Cancer

  2023cites this paper
• Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

  2023cites this paper
• Challenges and emerging strategies for next generation liposomal based drug delivery: An account of the breast cancer conundrum.

  2022cites this paper
• Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy.

  2022cites this paper
• Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery

  2022cites this paper
• Two branched fructose modification improves tumor targeting delivery of liposomes to breast cancer in intro and in vivo

  2021cites this paper
• Delivery of siRNA by gold nanoparticles layer by layer for prevention and control of subgroup J avian leukemia virus (ALV-J)

  2021cites this paper
• Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma

  2021cites this paper
• BIOI Virtual Academic Series PART 2: Frontiers and Multidisciplinarity in Nanomedicine

  2020cites this paper
• Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems

  2020cites this paper
• Fibronectin in the Tumor Microenvironment.

  2020cites this paper
• The Interaction of Colloid–Liposome–Protein Ternary Complex with Biological Membrane

  2020cites this paper
• Shape Matters: Comprehensive Analysis of Star-Shaped Lipid Nanoparticles

  2020cites this paper
• Multifunctional carriers for controlled drug delivery

  2020cites this paper
• miR-589-3p sponged by the lncRNA TINCR inhibits the proliferation, migration and invasion and promotes the apoptosis of breast cancer cells by suppressing the Akt pathway via IGF1R

  2020cites this paper
• Resistance to paclitaxel induces glycophenotype changes and mesenchymal-to-epithelial transition activation in the human prostate cancer cell line PC-3

  2020cites this paper
• Downregulation of MDR 1 gene contributes to tyrosine kinase inhibitor induce apoptosis and reduction in tumor metastasis: A gravity to space investigation.

  2020cites this paper
• siRNA therapeutics: a clinical reality

  2019cites this paper
• Phage display screening of therapeutic peptide for cancer targeting and therapy

  2019cites this paper
• A review on Targeting Nanoparticles for Breast Cancer.

  2019cites this paper
• Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux

  2019cites this paper
• Drug Nanorod-Mediated Intracellular Delivery of microRNA-101 for Self-sensitization via Autophagy Inhibition

  2019cites this paper
• Overcoming multiple drug resistance in cancer using polymeric micelles

  2018cites this paper
• A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis

  2018cites this paper
• Competitive Reactions in Three-Component System Cationic Colloid–Anionic Liposome–Protein

  2018cites this paper
• Triple therapy of hepatocellular carcinoma with microRNA-122 and doxorubicin co-loaded functionalized gold nanocages.

  2018cites this paper
• Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy

  2018cites this paper
• Bacterial cellulose hydrogel loaded with lipid nanoparticles for localized cancer treatment.

  2018cites this paper
• Two New Oxovanadium(iv) Compounds Containing Amino Acid Schiff Base and 1,10-Bathophenanthroline Ligands: Syntheses, Crystal Structures, and In Vitro Evaluation of the Anticancer Activities

  2017cites this paper
• Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship.

  2017cites this paper
• Mitochondria targeting and near-infrared fluorescence imaging of a novel heptamethine cyanine anticancer agent.

  2017cites this paper
• Co‐delivery of hypoxia inducible factor‐1α small interfering RNA and 5‐fluorouracil to overcome drug resistance in gastric cancer SGC‐7901 cells

  2017cites this paper
• Dual‐functional drug liposomes in treatment of resistant cancers☆

  2017cites this paper
• In vitro evaluation of the efficacy of selected medicinal plant extracts against multidrug resistant cancer cells

  2017cites this paper
• Drug Vectoring Systems To Target Drug Delivery Using Nanotechnologies

  2017cites this paper
• Nanomaterials for cancer therapies

  2017cites this paper
• Co-delivery of HIF-1α siRNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells

  year unknowncites this paper